PowerAI-CVD - the first Chinese-specific, validated artificial intelligence-powered in-silico predictive model for cardiovascular disease
Li, L.; Chou, O. H. I.; Lu, L.; Pui, H. H. H.; Lee, Q.; Kaur, N.; Wong, W. T.; Chang, C.; Liu, H.; Wai, A. K. C.; Cheung, B. M. Y.; Liu, T.; Tse, G.; Zhou, J.
Show abstract
BackgroundThe main risk stratification tools for identifying high-risk individuals of cardiovascular disease (CVD) are based on Western populations. Few models are developed specifically for Asian populations and are not enhanced by artificial intelligence (AI). The aim of this study is to develop the first AI-powered quantitative predictive tool for CVD (PowerAI-CVD) incorporate physiological blood pressure measurements, existing diseases and medications, and laboratory tests from Chinese patients. MethodsThe study analysed patients who attended family medicine clinics between 1st January 2000 and 31st December 2003. The primary outcome was major adverse cardiovascular events (MACE) defined as a composite of myocardial infarction, heart failure, transient ischaemic attack (TIA)/stroke or cardiovascular mortality, with follow-up until 31st December 2019. The performance of AI-driven models (CatBoost, XGBoost, Gradient Boosting, Multilayer Perceptron, Random Forest, Naive Bayes, Decision Tree, k-Nearest Neighbor, AdaBoost, SVM-Sigmod) for predicting MACE was compared. Predicted probability (ranging between 0 and 1) of the best model (CatBoost) was used as the baseline in-silico marker to predict future MACE events during follow-up. ResultsA total of 154,569 patients were included. Over a median follow-up of 16.1 (11.6-17.8) years, 31,061 (20.44%) suffered from MACE (annualised risk: 1.28%). The machine learning in-silico marker captured MACE risk from established risk variables (sex, age, mean systolic and diastolic blood pressure, existing cardiovascular diseases, medications (anticoagulants, antiplatelets, antihypertensive drugs, and statins) and laboratory tests (NLR, creatinine, ALP, AST, ALT, HbA1c, fasting glucose, triglyceride, LDL and HDL)). MACE incidences increased quantitatively with ascending quartiles of the in-silico marker. The CatBoost model showed the best performance with an area under the receiver operating characteristic curve of 0.869. The CatBoost model based in-silico marker shows significant prediction strength for future MACE events, across subgroups (age, sex, prior MACE, etc) and different follow-up durations. ConclusionsThe AI-powered risk prediction tool can accurately forecast incident CVD events, allowing personalised risk prediction at the individual level. A dashboard for predictive analytics was developed, allowing real-time dynamic updates of risk estimates from new data. It can be easily incorporated into routine clinical use to aid clinicians and healthcare administrators to identify high-risk patients. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=114 SRC="FIGDIR/small/23296722v1_ufig1.gif" ALT="Figure 1"> View larger version (38K): org.highwire.dtl.DTLVardef@968120org.highwire.dtl.DTLVardef@f78535org.highwire.dtl.DTLVardef@4a7ffforg.highwire.dtl.DTLVardef@11978f7_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development and validation of a cardiovascular diseases risk prediction model for Chinese males (CVDMCM) 94%
- Predicting long-term prognosis after percutaneous coronary intervention in patients with acute coronary syndromes: a prospective nested case-control analysis for county-level health services 94%
- Estimation of Life’s Essential 8 Score with Incomplete Data of Individual Metrics 93%
Similar papers in this journal
- Prediction of Cardiovascular Markers and Diseases Using Retinal Fundus Images and Deep Learning: A Systematic Scoping Review 94%
- Using ECG Machine Learning for Detection of Cardiovascular Disease in African American Men and Women: the Jackson Heart Study 94%
- International Evaluation Of An Artificial Intelligence-Powered Ecg Model Detecting Occlusion Myocardial Infarction 92%
Similar papers in this journal
- Can machine learning improve risk prediction of incident hypertension? An internal method comparison and external validation of the Framingham risk model using HUNT Study data 96%
- Nationwide prediction of type 2 diabetes comorbidities 93%
- Metformin Is Associated with Favorable Outcomes in Patients with COVID-19 and Type 2 Diabetes Mellitus 93%
Similar papers in this journal
- Actionable absolute risk prediction of atherosclerotic cardiovascular disease: a behavior-management approach based on data from 464,547 UK Biobank participants 96%
- Economic Evaluation of Hypertension screening in Iran using Markov model 94%
- Leveraging Machine Learning for Enhanced and Interpretable Risk Prediction of Venous Thromboembolism in Acute Ischemic Stroke Care 94%
Similar papers in this journal
- Effectiveness of An Impedance Cardiography Guided Treatment Strategy to Improve Blood Pressure Control in A Real-World Setting: Results from A Pilot Pragmatic Clinical Trial 93%
- Machine learning approaches to predict 30-day mortality following percutaneous coronary intervention in an Australian population 93%
- Impact of COVID-19 on recorded blood pressure screening and hypertension management in England: An analysis of monthly changes in Quality and Outcomes Framework indicators in OpenSAFELY 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.